Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial

The purpose of this work was to use data from a large co-operative group trial to evaluate whether metabolic FDG-PET changes in the heart for lung cancer patients can predict for clinical outcomes. The study found that cardiac SUV changes following definitive chemoradiation are significantly (HR 0.8...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Ryan, Santangelo, Tess, Forghani-Arani, Farnoush, Rusthoven, Chad, Chen, Yingxuan, Castillo, Edward, Castillo, Richard, Guerrero, Thomas, Vinogradskiy, Yevgeniy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660739/
https://www.ncbi.nlm.nih.gov/pubmed/35413391
http://dx.doi.org/10.1016/j.radonc.2022.04.003
_version_ 1784830437831475200
author Miller, Ryan
Santangelo, Tess
Forghani-Arani, Farnoush
Rusthoven, Chad
Chen, Yingxuan
Castillo, Edward
Castillo, Richard
Guerrero, Thomas
Vinogradskiy, Yevgeniy
author_facet Miller, Ryan
Santangelo, Tess
Forghani-Arani, Farnoush
Rusthoven, Chad
Chen, Yingxuan
Castillo, Edward
Castillo, Richard
Guerrero, Thomas
Vinogradskiy, Yevgeniy
author_sort Miller, Ryan
collection PubMed
description The purpose of this work was to use data from a large co-operative group trial to evaluate whether metabolic FDG-PET changes in the heart for lung cancer patients can predict for clinical outcomes. The study found that cardiac SUV changes following definitive chemoradiation are significantly (HR 0.811, 95% CI 0.68–0.96, p = 0.017) associated with overall survival in locally advanced NSCLC patients. If validated in a prospective cohort, our data show the potential for cardiac metabolic changes to be an early predictor for clinical outcomes.
format Online
Article
Text
id pubmed-9660739
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-96607392022-11-14 Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial Miller, Ryan Santangelo, Tess Forghani-Arani, Farnoush Rusthoven, Chad Chen, Yingxuan Castillo, Edward Castillo, Richard Guerrero, Thomas Vinogradskiy, Yevgeniy Radiother Oncol Article The purpose of this work was to use data from a large co-operative group trial to evaluate whether metabolic FDG-PET changes in the heart for lung cancer patients can predict for clinical outcomes. The study found that cardiac SUV changes following definitive chemoradiation are significantly (HR 0.811, 95% CI 0.68–0.96, p = 0.017) associated with overall survival in locally advanced NSCLC patients. If validated in a prospective cohort, our data show the potential for cardiac metabolic changes to be an early predictor for clinical outcomes. 2022-06 2022-04-10 /pmc/articles/PMC9660739/ /pubmed/35413391 http://dx.doi.org/10.1016/j.radonc.2022.04.003 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Article
Miller, Ryan
Santangelo, Tess
Forghani-Arani, Farnoush
Rusthoven, Chad
Chen, Yingxuan
Castillo, Edward
Castillo, Richard
Guerrero, Thomas
Vinogradskiy, Yevgeniy
Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial
title Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial
title_full Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial
title_fullStr Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial
title_full_unstemmed Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial
title_short Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial
title_sort changes in post-treatment cardiac pet avidity predict overall survival in lung cancer patients treated with chemoradiation: secondary analysis of the acrin 6668/rtog 0235 clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660739/
https://www.ncbi.nlm.nih.gov/pubmed/35413391
http://dx.doi.org/10.1016/j.radonc.2022.04.003
work_keys_str_mv AT millerryan changesinposttreatmentcardiacpetaviditypredictoverallsurvivalinlungcancerpatientstreatedwithchemoradiationsecondaryanalysisoftheacrin6668rtog0235clinicaltrial
AT santangelotess changesinposttreatmentcardiacpetaviditypredictoverallsurvivalinlungcancerpatientstreatedwithchemoradiationsecondaryanalysisoftheacrin6668rtog0235clinicaltrial
AT forghaniaranifarnoush changesinposttreatmentcardiacpetaviditypredictoverallsurvivalinlungcancerpatientstreatedwithchemoradiationsecondaryanalysisoftheacrin6668rtog0235clinicaltrial
AT rusthovenchad changesinposttreatmentcardiacpetaviditypredictoverallsurvivalinlungcancerpatientstreatedwithchemoradiationsecondaryanalysisoftheacrin6668rtog0235clinicaltrial
AT chenyingxuan changesinposttreatmentcardiacpetaviditypredictoverallsurvivalinlungcancerpatientstreatedwithchemoradiationsecondaryanalysisoftheacrin6668rtog0235clinicaltrial
AT castilloedward changesinposttreatmentcardiacpetaviditypredictoverallsurvivalinlungcancerpatientstreatedwithchemoradiationsecondaryanalysisoftheacrin6668rtog0235clinicaltrial
AT castillorichard changesinposttreatmentcardiacpetaviditypredictoverallsurvivalinlungcancerpatientstreatedwithchemoradiationsecondaryanalysisoftheacrin6668rtog0235clinicaltrial
AT guerrerothomas changesinposttreatmentcardiacpetaviditypredictoverallsurvivalinlungcancerpatientstreatedwithchemoradiationsecondaryanalysisoftheacrin6668rtog0235clinicaltrial
AT vinogradskiyyevgeniy changesinposttreatmentcardiacpetaviditypredictoverallsurvivalinlungcancerpatientstreatedwithchemoradiationsecondaryanalysisoftheacrin6668rtog0235clinicaltrial

Ejemplares similares